Category: Health

  • Study Says Two AIDS viruses originated in gorillas of Cameroon

    Study Says Two AIDS viruses originated in gorillas of Cameroon

    {Two of the four known groups of human AIDS viruses originated in western lowland gorillas in Cameroon, scientists said. The virus that causes almost all the cases of AIDS worldwide, called HIV-1, has jumped species to infect humans on at least four separate occasions, generating four HIV-1 lineages – groups M, N, O, and P, Xinhua reported on Monday.}

    Previous research has found that groups M and N originated in geographically distinct chimpanzee communities in southern Cameroon, but the origins of groups O and P remained uncertain. The new study, published in the U.S. journal Proceedings of the National Academy of Sciences, conducted a comprehensive survey of simian immunodeficiency virus (SIV) infection in African gorillas. The scientists screened faecal samples from western lowland gorillas, eastern lowland gorillas, and mountain gorillas in Cameroon, Gabon, the Democratic Republic of Congo, and Uganda for the presence of SIVs that are thought to be the precursors of HIV- 1. They identified four field sites in southern Cameroon where western lowland gorillas harbour SIVs. (Read: HIV diagnosis — 5 tests to detect a recent HIV infection)

    ‘Viral sequencing revealed a high degree of genetic diversity among the different gorilla samples,’ said co-author Professor Beatrice Hahn of Pennsylvania University in a statement. ‘Two of the gorilla virus lineages were particularly closely related to HIV-1 groups O and P. This told us that these two groups originated in western lowland gorillas.’ Martine Peeters of the University of Montpellier in France, who led the study, said the finding is critical to gauge future human infection risks. ‘From this study and others that our team has conducted in the past it has become clear that both chimpanzees and gorillas harbour viruses that are capable of crossing the species barrier to humans and have the potential to cause major disease outbreaks,’ Peeters added. HIV-1′s four known groups have had very different outcomes in humans. (Read: 9 factors that increase your risk for HIV)

    Group M gave rise to the AIDS pandemic, infecting more than 40 million people worldwide by spreading across Africa and throughout the rest of the world. Groups N and P, at the other extreme, have only been found in a few individuals from Cameroon. But group O, although not as widespread and prevalent as group M, has nonetheless infected about 100,000 people in Africa. Another virus type, called HIV-2, also causes AIDS, but is endemic only in West Africa. (Read: Rapid HIV tests to detect ailment in 15-20 minutes!)

    Source: IANS

  • Millicom Joins GSMA’s Mobile Health Partnership in Africa

    Millicom Joins GSMA’s Mobile Health Partnership in Africa

    Millicom (STO:MIC) (NASDAQ:MICC) announced today that it has joined the GSMA’s cross-ecosystem Pan-African mHealth initiative (PAMI) which is designed to connect people with the mobile industry and health services in eleven countries in Sub-Saharan Africa, including the Tigo operations in Ghana, Rwanda and Tanzania.

    PAMI aims to develop commercially sustainable and scalable mHealth services that meet public health needs. The primary objective is to offer relevant services to women and children, with a particular focus on nutrition.

    Millicom will work closely with the GSMA and other partners in the initiative to provide mobile access to affordable and reliable healthcare information for its customers.

    Commenting on the partnership, Millicom’s EVP for External Affairs Rachel Samrén said: “Millicom always strives to offer first-class mobile technology and digital services but also to provide convenience in people’s lives – whether through existing offers like mobile financial services or by enabling customers to learn English or now to benefit from mobile health services. This partnership with the GMSA aims to make much needed healthcare services more accessible and affordable for our customers.”

    “The GSMA is working with mobile operators across Africa to provide vulnerable women and children with free access to a suite of basic health and nutrition services, delivered through a single consolidated access point on their mobile phones,” said Tom Phillips, Chief Regulatory Officer, GSMA. “The GSMA is delighted that Millicom has joined the initiative to work together to deliver solutions that positively impact on the lives of both consumers and health workers and that deliver public health needs.”

    With its partners, Tigo operations will aim to create a strong relationship between other mobile and health stakeholders and use the ubiquity of its mobile technology and its capabilities to benefit health providers and patients.

    {{Press Release}}

  • For Your Health: Running   Health Benefits of Running

    For Your Health: Running Health Benefits of Running

    {We know that running is a great way to get physically fit. But how does it affect the body?}

    The most obvious effect of running is that it burns calories and raises the metabolic rate—the rate at which the body uses energy. This can help control weight. Running also builds and tones the muscles, particularly in the lower half of the body. Being toned and fit makes it easier to do other physical activities. But running, and any other form of regular exercise, also affects other systems of the body.

    Running is a form of aerobic exercise—the heart rate increases during this activity. When the heart rate is raised, the whole cardiovascular system (the heart and blood vessels) gets a workout. Regular workouts make the cardiovascular system run more efficiently. But what does this mean? The heart is a muscle, so when the heart rate gets raised during exercise, the heart gets exercise. Regular exercise makes the heart, and the other parts of the cardiovascular system, stronger and helps it run more efficiently. The heart pumps more blood with each beat. This in turn helps the blood vessels retain elasticity. The increased volume of blood also carries more oxygen from the lungs to the other parts of the body. The lungs get a workout as well, because of the increased breathing rate during a run.

    But why are these effects important? Weight control plays a leading role in preventing type 2 diabetes, a disease in which the sugars in food are not properly metabolized. This disease is growing dramatically around the world, particularly in countries undergoing rapid industrialization. People with diabetes are more likely to develop kidney disease, cardiovascular disease, blindness, gangrene, and other illnesses.

    Regular exercise reduces blood pressure, thereby helping to control hypertension (high blood pressure). Exercise also raises the good cholesterol (high-density lipoproteins, or HDL) and lowers the bad cholesterol (low-density lipoproteins, or LDL), the kind of cholesterol that builds up in the arteries. All of this helps prevent heart attacks and strokes, as well as other cardiovascular diseases.

    Another advantage of running is that it is a weight-bearing exercise. Exercise in which muscles pull on bones helps stimulate bone building. This makes them stronger and healthier.

    If any aerobic, weight-bearing exercise gives the body a good overall workout, why choose running? The answer is the simplicity of the activity. Running can be done outside on roads or indoors on a track or treadmill. It requires very little equipment beyond good running shoes, and it can be done in warm or cold weather.

    {{Source: Planetseed.com}}

  • Be Warned: Internet Use Can Be Addictive

    Be Warned: Internet Use Can Be Addictive

    {A study conducted by Intersperience, an international consumer research organization, queried 1,000 participants in the U.K., aged 18-65. The participants answered a lengthy questionnaire and were requested to refrain from any internet use for 24 hours. }

    Probably the biggest stumbling block for the respondents was actually stepping away from the internet. For some, the thought was inconceivable. Others labeled it one of the hardest things they had done, likening it to a nightmare. Some even had symptoms of withdrawal, similar to drugs or alcohol addictions.

    “Online and digital technology is increasingly pervasive,” said Paul Hudson, chief executive of Intersperience. “Ourr esearch shows how just dominant a role it now assumes, influencing our friendships, the way we communicate, the fabric of our family life, our work lives, our purchasing habits and our dealings with organizations.”

    Younger people had a more difficult time unplugging, that did their over-40 counterparts, and very few people embraced wholeheartedly the concept of an internet-free life, even for a mere 24 hours. Fifty-three percent acknowledged being upset when denied access ot the internet, while 40 percent indicated they were lonely when unable to communicate with friends on the internet.

    “The way we engage with technology has occurred faster than many of us had anticipated,” said Hudson. “This has profound implications for society both from a personal and commercial perspective.”

    {{Source: Health News}}

  • SFH Rwanda Launches Prudence condoms rebranding campaign

    SFH Rwanda Launches Prudence condoms rebranding campaign

    {{Kigali}} – {This week, the Society for Family Health (SFH) Rwanda, with funding support from the American People through the United States Agency for International Development (USAID) through its Rwanda Social Marketing Program, launches a rebranding campaign of popular local condom brand Prudence.}

    For the second time, ten years after its facelift in 2006, Prudence condoms are being rebranded to suit the interests and standards of its users. The Prudence condom brand was first launched in Rwanda in 1995 as “PRUDENCE PLUS” and later in 2006 changed to be called Prudence.

    In this latest campaign, the brand name Prudence will be maintained and will gain a new brand logo the new look and the associated campaign seek to appeal to more young people and at-risk populations – with the ultimate goal of scaling up efforts to prevent the spread of HIV/AIDS and other sexually transmitted diseases in Rwanda.

    The Prudence rebranding campaign supports the goal of the USAID Rwanda Social Marketing Program to sustainably improve the health and nutrition status of all Rwandans by making essential health commodities available to the Rwandan public through awareness campaigns on the benefits of products like condoms and bed nets, the correct use of these products, and making them more widely available across the country. The health sector remains USAID’s largest sector of support in Rwanda, with approximately $76 million invested each year in areas from HIV prevention and treatment to heath systems strengthening.

    The campaign will last for 12 months, and will include outreach in various forms including radio, television, and popular local events such as football matches. All of these events are part of SFH’s larger efforts, as Rwanda’s leading social marketing organization, to fight HIV/AIDS and ensure all Rwandans have access to the information and products they need to make healthy decisions and live healthy lives.
    {
    For More Information
    Contact:
    Butera John Robert Mugabe
    Corporate Communications Manager
    Email: rbutera@sfhrwanda.org
    Mobile: 0788385109}

  • Student ‘expelled for having genetic blood disease’

    Student ‘expelled for having genetic blood disease’

    BEIJING – {A student in Beijing is suing his university after he was allegedly expelled for having the rare hereditary blood disease haemophilia, reports said Friday, the latest case in China’s long history of medical discrimination.}

    The student, identified by the pseudonym Zheng Qing, is suing the China Institute of Industrial Relations after he was officially expelled earlier this month, the government-run Global Times reported.

    He was previously pressured into leaving the school in September.

    The 21-year-old journalism major applied to be excused from mandatory military training on account of his haemophilia, a genetic disorder in which a patient’s blood does not clot properly, forcing them to have regular transfusions to replace the missing clotting protein.

    The disease is not contagious and Zheng would not be able to infect his fellow classmates.

    But the school expelled him under a 2003 education ministry rule saying that universities could “refuse the admission of students who have serious blood diseases”.

    The student’s lawyer, Wang Qiushi, was quoted as saying that regulation referred to students who “cannot finish their studies or cannot take care of themselves”.

    China has a long history of ostracising patients suffering from certain illnesses.

    People with HIV and AIDS have faced discrimination in the Chinese job market for years and foreigners with the virus were banned from obtaining visas until 2010.

    In December, more than 200 people signed a petition to expel an HIV-positive eight-year-old boy from their village, prompting a national debate and highlighting the stigma involved.

    AFP

  • Pope: Catholics don’t have to breed ‘like rabbits’

    Pope: Catholics don’t have to breed ‘like rabbits’

    ({{AP}}) — {Pope Francis is firmly upholding church teaching banning contraception, but said Monday that Catholics don’t have to breed “like rabbits” and should instead practice “responsible parenting.”}

    Speaking to reporters en route home from the Philippines, Francis said there are plenty of church-approved ways to regulate births. But he said most importantly, no outside institution should impose its views on regulating family size, blasting what he called the “ideological colonization” of the developing world.

    African bishops, in particular, have long complained about how progressive, Western ideas about birth control and gay rights are increasingly being imposed on the developing world by groups, institutions or individual nations, often as a condition for development aid.

    “Every people deserves to conserve its identity without being ideologically colonized,” Francis said.

    The pope’s comments, taken together with his defense of the Catholic Church’s ban on artificial contraception during the trip, signal that he is increasingly showing his more conservative bent, which has largely been ignored by public opinion or obscured by a media narrative that has tended to highlight his populist persona.

    On the trip, Francis gave his strongest defense yet of the 1968 encyclical Humanae Vitae, which enshrined the church’s opposition to artificial birth control. He warned against “insidious attacks” against the family — a reference to gay marriage proposals — echoing language often used by overwhelmingly conservative U.S. bishops. And he insisted that “openness to life is a condition of the sacrament of matrimony.”

    At the same time, however, he said it’s not true that to be a good Catholic “you have to be like rabbits.” On the contrary, he said “responsible parenthood” requires that couples regulate the births of their children, as church teaching allows. He cited the case of a woman he met who was pregnant with her eighth child after seven Cesarean sections.

    “That is an irresponsibility!” he said. The woman might argue that she should trust in God. “But God gives you methods to be responsible,” he said.

    He said there are many “licit” ways of regulating births that are approved by the church, an apparent reference to the Natural Family Planning method of monitoring a woman’s cycle to avoid intercourse when she is ovulating.

    During the Vatican’s recent meeting on the family, African bishops denounced how aid groups and lending institutions often condition their assistance on a country’s compliance with their ideals: allowing health care workers to distribute condoms, or withdrawing assistance if legislation discriminating against gays is passed.

    “When imposed conditions come from imperial colonizers, they search to make people lose their own identity and make a sameness,” he said. “This is ideological colonization.”

  • Meningitis Vaccine Wipes Out Disease In Sub-Saharan Africa

    Meningitis Vaccine Wipes Out Disease In Sub-Saharan Africa

    {Sub-Saharan Africa is the continent’s “meningitis belt” no more thanks to the efforts of a global team of scientists, drugmakers, and philantrophists who created a tailor-made and affordable vaccine against the deadly disease.}

    “We have not seen a single case among vaccinated populations,” said Marie Pierre-Preziosi, Meningitis Vaccine Project (M.V.P.) director, “and transmission has stopped.”

    Victory of the region, which stretches from Senegal to Ethiopia, against the disease can be attributed to the M.V.P., which is set to close after rolling out a special vaccine barely in 2010. M.V.P., a partnership between the World Health Organization (W.H.O.) and Program for Appropriate Technology in Health (P.A.T.H.) pioneered in what may be a model for handling infectious diseases in developing countries, Reuters wrote.

    MenAfriVac, produced by the generic drugmaker Serum Institute of India and with funding from the Bill & Melinda Gates Foundation, was tested, put on trial, and deployed in record time, saving thousands of lives from the “A” strain of meningitis in just a few years. Meningococcal meningitis, which cause severe brain damage, deafness, epilepsy or necrosis and, if untreated, death in 50 percent of cases, has infected 250,000 and killed over 25,000 in 1996 to 1997 in what was considered as one of Africa’s worst recorded outbreaks. In 2008 to 2009, an epidemic in Nigeria resulted to 56,000, almost three times the number of Ebola cases in West Africa.

    The W.H.O. authorized MenAfriVac on Friday to be included in routine child immunizations in Africa.

    The single-strain vaccine comes with a price tag of only 50 U.S. cents a shot, compared to its expensive predecessors which target four strains, A, C, Y and W-135.

    “African health officials told us: ‘Don’t come with a vaccine we cannot afford, because that would not be a solution’,” Pierre-Preziosi said.

    MenAfriVac is the first vaccine to be made especially for Africa and does not need constant refrigeration considering the region’s hot climate.

    Since its introduction in Burkina Faso in 2010, over 217 million people in 15 countries have received the vaccine.

    Mass vaccination campaigns will continue this year in Ethiopia and in four new countries: Democratic Republic of Congo, Guinea, Guinea Bissau, South Sudan.

    Next year, Burundi, Central African Republic, Eritrea, Kenya, Rwanda, Uganda, and Tanzania will be the seven last African countries to hold such campaigns.

  • Ebola Doctors Are Divided on IV Therapy in Africa

    Ebola Doctors Are Divided on IV Therapy in Africa

    Medical experts seeking to stem the Ebola epidemic are sharply divided over whether most patients in West Africa should, or can, be given intravenous hydration, a therapy that is standard in developed countries. Some argue that more aggressive treatment with IV fluids is medically possible and a moral obligation. But others counsel caution, saying that pushing too hard would put overworked doctors and nurses in danger and that the treatment, if given carelessly, could even kill patients.

    The debate comes at a crucial time in the outbreak. New infections are flattening out in most places, better-equipped field hospitals are opening, and more trained professionals are arriving, opening up the possibility of saving many lives in Africa, rather than a few patients flown to intensive care units thousands of miles away.

    The World Health Organization sees intravenous rehydration, along with constant measuring of blood chemistry, as the main reason that almost all Ebola patients treated in American and European hospitals have survived, while about 70 percent of those treated in West Africa have died.

    Every hospital there should have “early, liberal use of intravenous fluid and electrolyte replacement,” said Dr. Robert A. Fowler, a Canadian critical care specialist who leads a W.H.O. Ebola team. Anything less, he said, is “not medically justified and will result in continued high case-fatality rates.”

    Experts who favor aggressive rehydration point to several hospitals that claim unusually low death rates as evidence that it is effective. Skeptics say other factors may be at work.

    Even two of the most admired medical charities have squared off over the issue. Partners in Health, which has worked in Haiti and Rwanda but is just beginning to treat Ebola patients in West Africa, supports the aggressive treatment. Its officials say the more measured approach taken by Doctors Without Borders is overly cautious.

    “M.S.F. is not doing enough,” said Dr. Paul Farmer, one of the founders of Partners in Health, using the French initials for Doctors Without Borders, whose staff members have worked on the front lines of Ebola outbreaks for years. “What if the fatality rate isn’t the virulence of disease but the mediocrity of the medical delivery?”

    Doctors Without Borders representatives strongly disagreed, saying that Dr. Farmer’s assumptions about Ebola were incorrect, that intensive rehydration would probably not save as many patients as he believes, and that the W.H.O.’s position has not been proved.

    The group’s overwhelmed doctors do what they can, officials said, but it is hard to insert needles while wearing three pairs of gloves and foggy goggles. IVs must be monitored, drawing virus-laden blood for tests is dangerous, and patients yank needles out — sometimes in delirium, sometimes just to go to the toilet when no nurse is around.

    Ebola patients lose up to five quarts of fluid a day through diarrhea and vomiting. In that fluid are electrolytes like potassium, magnesium, sodium and calcium, and proteins like albumin. Electrolyte loss can stop the heart; protein loss can cause fatal internal swelling.
    Continue reading the main story

    Rehydrating patients and replacing those elements “is the antidote to the idea that everybody’s going to die,” Dr. Farmer said.

    Every Ebola hospital, he argued, should have a team that specializes in inserting IVs — or, better yet, peripherally inserted central catheters, or PICC lines. These are thin plastic tubes, inserted in the arm or chest and threaded through a vein, that can be left in place for days and the needle discarded.

    Along with doctors at the London School of Hygiene and Tropical Medicine, who published an article on rehydration in The Lancet on Dec. 4, Dr. Farmer has also called for the use of thick needles driven into bone marrow with surgical “guns.” This procedure, known as intraosseous infusion, is slow, but it reinflates veins too shrunken to admit an intravenous line, and the needles are much harder for agitated patients to pull out.

    However, not all doctors know how to use PICC lines or bone needles, or how to inject fluids into empty abdominal spaces, another technique endorsed in the Lancet article. (The article was accompanied by a video in which Dr. Ian Roberts, the chief author, had some of those techniques demonstrated on himself. He used minimal anesthesia, he said, to imitate field conditions in West Africa.)

    Doctors Without Borders normally puts IV lines in as many Ebola patients as it can manage, said Dr. Armand Sprecher, an Ebola expert with the organization. That practice was temporarily stopped in September, when the disease was spreading so fast that doctors had only one minute per patient during the one hour they could work in their sweltering protective suits.

    The fatality rate across the group’s six Ebola treatment centers in West Africa was about 60 percent then, and is now 40 to 50 percent, Dr. Sprecher said. He disputed Dr. Farmer’s contention that rehydration could bring it down to 10 percent.

    “It would probably push it down some, but I’d be surprised if it were dramatic,” Dr. Sprecher said.

    Dr. Farmer cited the treatment given at a unit in Hastings, Sierra Leone, as an example of the kind of care he endorses.

    In a Dec. 24 letter to The New England Journal of Medicine, the Sierra Leonean doctors running that center with Western advisers said they had had a 48 percent fatality rate when they opened in September and had since reduced it to 24 percent.

    Each of the 581 patients the center has treated immediately received IV fluids with electrolytes, they wrote. Even without lab tests, each patient also received an antibiotic, an anti-parasitic drug, an antimalarial drug, an anti-vomiting drug, pain pills, vitamins, zinc and a nutrition supplement.

    “That’s effective case management,” Dr. Farmer said. “We’re cheering them on.”

    The fatality rate at the unit Partners in Health runs in Port Loko, Sierra Leone, is 35 to 40 percent, its director, Dr. Corrado Cancedda, estimated.

    Up to 80 percent of patients there receive IV rehydration, Dr. Cancedda said, and some have had bone needles inserted; no PICC lines have been used. Battery-powered electrolyte monitoring machines are being introduced.

    Dr. Sprecher said death rates at Doctors Without Borders’ six hospitals in the region varied, with the lowest being 36 percent in Bo, Sierra Leone.

    But he could not explain why. Some of the hospitals see more young adults, who tend to survive. At rural centers, the sickest patients die on the way there.

    Rehydration was only one lifesaving factor for the handful of patients transported to American or European hospitals, Dr. Sprecher argued, because all of them also received intensive nursing, and some received dialysis, ventilation and experimental therapies.

    He was reluctant to have his doctors seen using bone-needle guns on patients. “Not long ago, we were being accused of stealing organs,” he said. “You have to be sure people understand what the heck you’re doing.”

    Dr. Sprecher also disputed Dr. Farmer’s comparison of Ebola to cholera, which both medical charities fight with aggressive rehydration. Ebola, he said, does more organ damage and makes blood vessels leak fluid.

    “In cholera, you can get fatalities down from 50 percent to 1 percent,” he said. “We’ve been putting people on IVs for Ebola for 14 years. If just tanking them up worked, we’d be doing it.”

    Lab testing is a crucial issue. For example, while low potassium can kill, so can overdoses. Potassium is used in executions by lethal injection.

    West Africa has at least eight laboratories run by various American, Canadian and European government agencies, Dr. Sprecher said. Until recently, they tested only for Ebola and diseases that mimic it, like malaria or Lassa fever.

    Now, he said, about half can test for electrolytes.

    Because heat and humidity knock out the machines that analyze blood chemistry, labs must be air-conditioned, said Dr. Thomas R. Frieden, director of the Centers for Disease Control and Prevention. The C.D.C. runs two large laboratories in the region, only one of which now tests for electrolytes.

    Sometimes, conservative guesswork is called for, Dr. Frieden said. His father, a physician, gave potassium to patients who needed IV rehydration long before such tests were routine.

    The best-equipped treatment center in West Africa is the 25-bed United States Public Health Service hospital in Monrovia, Liberia, which is reserved for doctors, nurses, burial teams and others fighting the epidemic. It is fully air-conditioned and has 32 medical personnel, who wear high-tech protective gear that sucks in fresh air. Its on-site lab tests blood for electrolytes and proteins. The pharmacy has drugs to raise blood pressure or increase coagulation, and patients can be fed through tubes.

    Since it opened in November, it has had 14 Ebola patients. Seven recovered, five died, one was transferred and one is in treatment, a spokeswoman said. (Ten other people who were admitted did not have Ebola.) That is a 42 percent fatality rate, though based on a small sample, for the 12 patients whose fates are clear.

    Other units tread a middle ground, relying on what measures they have at hand. The fatality rate at the International Medical Corps hospital in Bong County, Liberia, is about 55 percent, said Dr. Pranav Shetty, the agency’s international emergency health coordinator.

    All patients who need IV lines get them, Dr. Shetty said. But when there are too few nurses around, usually at night, the IVs are unhooked, so patients may get only one quart of fluids a day. And only patients still urinating, indicating that their kidneys are working, receive electrolytes.

    Spending money on air-conditioning “doesn’t even cross our minds,” Dr. Shetty said, because other needs are more urgent.

    When IV lines are impractical, the W.H.O. urges doctors to make patients drink six quarts of rehydration solution a day.

    Nigeria’s victory over its Ebola outbreak in September was attributed in part to that. Dr. Adaora Igonoh, a 28-year-old Nigerian physician who survived the disease, became a symbol for the cause: The W.H.O. distributed pictures of her giving a thumbs-up while drinking the solution, and Bill Gates blogged about her story, telling how she forced herself to drink despite the repulsive salty taste and her vomiting.

    Still, even oral rehydration is hard, doctors say. Patients need anti-nausea drugs and must be pressured to drink. The solution tastes better when refrigerated. But, like air-conditioning, that requires electricity.

    {{The New York Times}}

  • Trial confirms Ebola vaccine candidate safe, equally immunogenic in Africa

    Trial confirms Ebola vaccine candidate safe, equally immunogenic in Africa

    {{Date:}} December 23, 2014
    {{Source}}: The Lancet
    {{Summary}}: {Two experimental DNA vaccines to prevent Ebola virus and the closely related Marburg virus are safe, and generated a similar immune response in healthy Ugandan adults as reported in healthy US adults earlier this year. The findings are from the first trial of filovirus vaccines in Africa.}

    Two experimental DNA vaccines to prevent Ebola virus and the closely related Marburg virus are safe, and generated a similar immune response in healthy Ugandan adults as reported in healthy US adults earlier this year. The findings, from the first trial of filovirus vaccines in Africa, are published in The Lancet.

    “This is the first study to show comparable safety and immune response of an experimental Ebola vaccine in an African population,” says lead author Dr Julie Ledgerwood from the National Institutes of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, USA. “This is particularly encouraging because those at greatest risk of Ebola live primarily in Africa, and diminished vaccine protection in African populations has been seen for other diseases.”

    Scientists from the NIAID developed the DNA vaccines that code for Ebola virus proteins from the Zaire and Sudan strains and the Marburg virus protein. The vaccines contain the construction plans for the proteins on the outer surface of the virus. Immune responses against these proteins have shown to be highly protective in non-human primate models.

    In this phase 1 trial, the Makerere University Walter Reed Program enrolled 108 healthy adults aged between 18 and 50 from Kampala, Uganda between November, 2009 and April, 2010. Each volunteer was randomly assigned to receive an intramuscular injection of either the Ebola vaccine (30 volunteers), Marburg vaccine (30), both vaccines (30), or placebo (18) at the start of the study, and again 4 weeks and 8 weeks later.

    The vaccines given separately and together were safe and stimulated an immune response in the form of neutralising antibodies and T-cells against the virus proteins. Four weeks after the third injection, just over half of the volunteers (57%; 17 of 30) had an antibody response to the Ebola Zaire protein as did 14 of 30 participants who received both the Ebola and Marburg vaccines. However, the antibodies were not long-lasting and returned to undetectable levels within 11 months of vaccination.

    Both DNA vaccines were well tolerated in Ugandan adults with similar numbers of local and systemic reactions reported in all groups. Only one serious adverse event (neutropenia; low white blood cell count) was reported in a Marburg vaccine only recipient, but was not thought to be vaccine related.

    According to Dr Ledgerwood, “These findings have already formed the basis of a more potent vaccine, delivered using a harmless chimpanzee cold virus, which is undergoing trials in the USA, UK, Mali, and Uganda in response to the ongoing Ebola virus outbreak.”

    Writing in a linked Comment, Dr Saranya Sridhar from the Jenner Institute at the University of Oxford in the UK says, “[This] study deserves to be the focal point around which the broader question of vaccine development, particularly for Africa, must be addressed. With the uncharitable benefit of hindsight in view of the evolving 2014 Ebola outbreak, we must ask ourselves whether a filovirus vaccine should have been in more advanced clinical development. The international response to the present Ebola outbreak is an exemplar of the speed and purpose with which clinical vaccine development can progress and has set the benchmark against which future vaccine development must be judged. This study is the first step on the aspirational road towards the deployment of filovirus vaccines in Africa and must serve to shake the metaphorical cobwebs that can stall our advance towards this destination.”